Details for Patent: 7,390,791
✉ Email this page to a colleague
Which drugs does patent 7,390,791 protect, and when does it expire?
Patent 7,390,791 protects SYMTUZA, BIKTARVY, DESCOVY, GENVOYA, ODEFSEY, and VEMLIDY, and is included in six NDAs.
Protection for BIKTARVY has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has seventy-five patent family members in thirty-four countries.
Summary for Patent: 7,390,791
| Title: | Prodrugs of phosphonate nucleotide analogues |
| Abstract: | A novel method has led to the identification of novel mixed ester-amidates of PMPA for retroviral or hepadnaviral therapy, including compounds of structure (5a) ##STR00001## having substituent groups as defined herein. Compositions of these novel compounds in pharmaceutically acceptable excipients and their use in therapy and prophylaxis are provided. |
| Inventor(s): | Becker; Mark W. (Belmont, CA), Chapman; Harlan H. (La Honda, CA), Cihlar; Tomas (Foster City, CA), Eisenberg; Eugene J. (San Carlos, CA), He; Gong-Xin (Fremont, CA), Kernan; Michael R. (Pacifica, CA), Lee; William A. (Los Altos, CA), Prisbe; Ernest J. (Los Altos, CA), Rohloff; John C. (Mountain View, CA), Sparacino; Mark L. (Morgan Hill, CA) |
| Assignee: | Gilead Sciences, Inc. (Foster City, CA) |
| Application Number: | 10/798,692 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 7,390,791 |
|
Patent Claim Types: see list of patent claims | Compound; Composition; Dosage form; |
Drugs Protected by US Patent 7,390,791
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Janssen Prods | SYMTUZA | cobicistat; darunavir; emtricitabine; tenofovir alafenamide fumarate | TABLET;ORAL | 210455-001 | Jul 17, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | |||
| Gilead Sciences Inc | BIKTARVY | bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate | TABLET;ORAL | 210251-002 | Oct 7, 2021 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Gilead Sciences Inc | BIKTARVY | bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate | TABLET;ORAL | 210251-001 | Feb 7, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Gilead Sciences Inc | DESCOVY | emtricitabine; tenofovir alafenamide fumarate | TABLET;ORAL | 208215-002 | Jan 7, 2022 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 7,390,791
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 1301519 | ⤷ Sign Up | 2016/014 | Ireland | ⤷ Sign Up |
| European Patent Office | 1301519 | ⤷ Sign Up | PA2016009 | Lithuania | ⤷ Sign Up |
| European Patent Office | 1301519 | ⤷ Sign Up | 300803 | Netherlands | ⤷ Sign Up |
| European Patent Office | 1301519 | ⤷ Sign Up | CA 2016 00012 | Denmark | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
